Plasma Protease C1-Inhibitor Global Market Report 2025

The plasma protease C1-inhibitor market size has grown rapidly in recent years. It will grow from $3.37 billion in 2024 to $3.85 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. Factors contributing to this historical growth include the rising prevalence of hereditary angioedema, increased awareness of rare genetic diseases, higher demand for biologics derived from plasma, improved diagnostics for C1-inhibitor deficiency, and expanded use of replacement therapy during emergency interventions.

The plasma protease C1-inhibitor market size is expected to see rapid growth in the next few years. It will grow to $6.53 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. Key drivers in the forecast period include a heightened emphasis on personalized treatment approaches, ongoing development of C1-inhibitor therapies in clinical pipelines, increasing preference for preventative treatment methods, broader access to at-home infusion solutions for C1-inhibitors, and greater recognition of C1-inhibitor deficiencies in preoperative and surgical contexts. Notable trends anticipated include a rise in orphan drug designations, advancements in low-immunogenicity drug formulations, incorporation of genomic technologies, expansion into telehealth platforms, and innovation in long-duration C1-inhibitor therapies.

The increasing investment in rare diseases is expected to drive the growth of the plasma protease C1-inhibitor market. Rare diseases are health conditions that impact a small percentage of the population, typically fewer than 1 in 2,000 individuals. These conditions are often chronic, progressive, and can be life-threatening or disabling. The rise in investment stems from the growing awareness of unmet medical needs and the potential for substantial returns through regulatory incentives such as orphan drug designation, market exclusivity, and lower development costs. This investment supports the development of plasma protease C1-inhibitors by funding research and innovation aimed at treating hereditary angioedema and other rare conditions linked to C1-inhibitor deficiencies, which can cause severe symptoms. For example, in April 2024, Global Genes, a US-based nonprofit organization, reported that companies developing drugs for rare diseases raised $7.1 billion in the first quarter of 2024, a 307% increase from the $1.8 billion raised in the same period in 2023. As a result, the increasing investment in rare diseases is propelling the plasma protease C1-inhibitor market forward.

Leading companies in the plasma protease C1-inhibitor market are concentrating on the development of advanced products, such as injectable prescription medicines, to provide rapid and effective relief for hereditary angioedema and enhance treatment results. Injectable prescription medicines are administered through injection and work by restoring or replacing plasma protease C1-inhibitor levels to control inflammation and prevent swelling episodes. For instance, in December 2022, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical firm, introduced CINRYZE in India. CINRYZE is the first injectable C1 esterase inhibitor approved by the FDA for prophylactic treatment in patients aged six years and older. It helps reduce the frequency, severity, and duration of hereditary angioedema (HAE) attacks by increasing plasma levels of C1-INH, thereby preventing excessive bradykinin production and controlling the associated swelling.

In December 2023, Danaher Corporation, a US-based conglomerate, acquired Abcam plc for $5.7 billion. This acquisition was intended to strengthen Danaher’s life sciences portfolio by improving its protein research tools and accelerating progress in disease mapping and drug discovery. Abcam plc is a UK-based biotechnology firm that offers various products related to plasma protease C1-inhibitor.

Major players in the plasma protease c1-inhibitor market are Takeda Pharmaceutical Company Limited, CSL Behring LLC, Sigma-Aldrich Co. LLC, Octapharma AG, Bio-Techne Corp, Ionis Pharmaceuticals Inc., Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc., Pharming Group N.V., Sino Biological Inc, Cayman Chemical, Enzo Life Sciences Inc, KalVista Pharmaceuticals Inc., Santa Cruz Biotechnology Inc, Pharvaris N.V, Attune Pharmaceuticals Inc., Biorbyt Ltd, Adverum Biotechnologies Inc, and Lev Pharmaceuticals.

North America was the largest region in the plasma protease C1-inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in plasma protease C1-inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the plasma protease C1-inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Plasma protease C1-inhibitors are medications that suppress the activity of plasma protease C1 within the complement system. Their main function is to regulate immune system activity by preventing overactivation of the complement cascade and managing inflammation. These inhibitors help sustain equilibrium within immune and coagulation pathways, thereby protecting tissues from inflammatory damage.

The primary categories of medications that act on plasma protease C1-inhibitor include C1-inhibitors, C1-esterase inhibitors, recombinant inhibitors, kallikrein inhibitors, and selective bradykinin B2 receptor antagonists. C1-inhibitors are naturally occurring blood proteins that modulate the complement system, an essential part of the immune defense against infection and inflammation. These treatments are commonly available in injectable and lyophilized formulations and are distributed through hospital pharmacies, retail drugstores, and online pharmacy platforms.

The plasma protease C1-inhibitor market research report is one of a series of new publications that offers insights into plasma protease C1-inhibitor market statistics, including the global market size, regional distribution, leading competitors by market share, detailed market segmentation, industry trends, and emerging opportunities. This comprehensive research report provides an all-encompassing view of the industry, with detailed analysis of both the current landscape and future projections.

The plasma protease C1-inhibitor market consists of sales of berinert, cinryze, haegarda, firazyr, and lcatibant. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.